Literature DB >> 19036964

Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3.

Xi Chen1, Tie-Shan Tang, Huiping Tu, Omar Nelson, Mark Pook, Robert Hammer, Nobuyuki Nukina, Ilya Bezprozvanny.   

Abstract

Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an autosomal-dominant neurodegenerative disorder caused by a polyglutamine expansion in ataxin-3 (ATX3; MJD1) protein. In biochemical experiments, we demonstrate that mutant ATX3(exp) specifically associated with the type 1 inositol 1,4,5-trisphosphate receptor (InsP(3)R1), an intracellular calcium (Ca(2+)) release channel. In electrophysiological and Ca(2+) imaging experiments, we show that InsP(3)R1 was sensitized to activation by InsP(3) in the presence of mutant ATX3(exp). We found that feeding SCA3-YAC-84Q transgenic mice with dantrolene, a clinically relevant stabilizer of intracellular Ca(2+) signaling, improved their motor performance and prevented neuronal cell loss in pontine nuclei and substantia nigra regions. Our results indicate that deranged Ca(2+) signaling may play an important role in SCA3 pathology and that Ca(2+) signaling stabilizers such as dantrolene may be considered as potential therapeutic drugs for treatment of SCA3 patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036964      PMCID: PMC2663415          DOI: 10.1523/JNEUROSCI.3909-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

Review 1.  Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology.

Authors:  G Stevanin; A Dürr; A Brice
Journal:  Eur J Hum Genet       Date:  2000-01       Impact factor: 4.246

Review 2.  Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons.

Authors:  Alexei Verkhratsky
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

3.  Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.

Authors:  M K Perez; H L Paulson; R N Pittman
Journal:  Hum Mol Genet       Date:  1999-12       Impact factor: 6.150

4.  Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.

Authors:  Jun Wu; Tieshan Tang; Ilya Bezprozvanny
Journal:  Neurosci Lett       Date:  2006-09-07       Impact factor: 3.046

5.  Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1.

Authors:  Omar Nelson; Huiping Tu; Tianhua Lei; Mostafa Bentahir; Bart de Strooper; Ilya Bezprozvanny
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

6.  Neuroprotective effects of early vs. late administration of dantrolene in experimental status epilepticus.

Authors:  M Niebauer; M Gruenthal
Journal:  Neuropharmacology       Date:  1999-09       Impact factor: 5.250

7.  Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.

Authors:  Y Chai; S L Koppenhafer; S J Shoesmith; M K Perez; H L Paulson
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

8.  Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.

Authors:  Tie-Shan Tang; Xi Chen; Jing Liu; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2007-07-25       Impact factor: 6.167

9.  Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.

Authors:  Ulrike Bichelmeier; Thorsten Schmidt; Jeannette Hübener; Jana Boy; Lukas Rüttiger; Karina Häbig; Sven Poths; Michael Bonin; Marlies Knipper; Werner J Schmidt; Johannes Wilbertz; Hartwig Wolburg; Franco Laccone; Olaf Riess
Journal:  J Neurosci       Date:  2007-07-11       Impact factor: 6.167

Review 10.  Dantrolene--a review of its pharmacology, therapeutic use and new developments.

Authors:  T Krause; M U Gerbershagen; M Fiege; R Weisshorn; F Wappler
Journal:  Anaesthesia       Date:  2004-04       Impact factor: 6.955

View more
  103 in total

1.  Suppression of calbindin-D28k expression exacerbates SCA1 phenotype in a disease mouse model.

Authors:  Parminder J S Vig; Jinrong Wei; Qingmei Shao; Maripar E Lopez; Rebecca Halperin; Jill Gerber
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

Review 2.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

3.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

4.  Role of presenilins in neuronal calcium homeostasis.

Authors:  Hua Zhang; Suya Sun; An Herreman; Bart De Strooper; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2010-06-23       Impact factor: 6.167

Review 5.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

Review 6.  Milestones in ataxia.

Authors:  Thomas Klockgether; Henry Paulson
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 7.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

9.  Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro.

Authors:  Guangbin Xia; Katherine Santostefano; Takashi Hamazaki; Jilin Liu; S H Subramony; Naohiro Terada; Tetsuo Ashizawa
Journal:  J Mol Neurosci       Date:  2012-12-09       Impact factor: 3.444

10.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.